BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21666690)

  • 21. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
    Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
    Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
    Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
    Front Immunol; 2019; 10():2355. PubMed ID: 31649670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
    Benlagha K; Weiss A; Beavis A; Teyton L; Bendelac A
    J Exp Med; 2000 Jun; 191(11):1895-903. PubMed ID: 10839805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface.
    Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB
    Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
    Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
    Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vβ2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen.
    Patel O; Pellicci DG; Uldrich AP; Sullivan LC; Bhati M; McKnight M; Richardson SK; Howell AR; Mallevaey T; Zhang J; Bedel R; Besra GS; Brooks AG; Kjer-Nielsen L; McCluskey J; Porcelli SA; Gapin L; Rossjohn J; Godfrey DI
    Proc Natl Acad Sci U S A; 2011 Nov; 108(47):19007-12. PubMed ID: 22065767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding.
    Sanderson JP; Waldburger-Hauri K; Garzón D; Matulis G; Mansour S; Pumphrey NJ; Lissin N; Villiger PM; Jakobsen B; Faraldo-Gómez JD; Gadola SD
    Eur J Immunol; 2012 Jan; 42(1):248-55. PubMed ID: 21956730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex.
    Sidobre S; Naidenko OV; Sim BC; Gascoigne NR; Garcia KC; Kronenberg M
    J Immunol; 2002 Aug; 169(3):1340-8. PubMed ID: 12133957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
    Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
    J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts.
    Lang GA; Maltsev SD; Besra GS; Lang ML
    Immunology; 2004 Jul; 112(3):386-96. PubMed ID: 15196206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hypervariable region 4 (HV4) and position 93 of the α chain modulate CD1d-glycolipid binding of iNKT TCRs.
    Paletta D; Fichtner AS; Hahn AM; Starick L; Beyersdorf N; Monzon-Casanova E; Mueller TD; Herrmann T
    Eur J Immunol; 2015 Jul; 45(7):2122-33. PubMed ID: 25900449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors.
    Brigl M; van den Elzen P; Chen X; Meyers JH; Wu D; Wong CH; Reddington F; Illarianov PA; Besra GS; Brenner MB; Gumperz JE
    J Immunol; 2006 Mar; 176(6):3625-34. PubMed ID: 16517731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.
    Li X; Shiratsuchi T; Chen G; Dellabona P; Casorati G; Franck RW; Tsuji M
    J Immunol; 2009 Oct; 183(7):4415-21. PubMed ID: 19734232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unappreciated diversity within the pool of CD1d-restricted T cells.
    Pellicci DG; Uldrich AP
    Semin Cell Dev Biol; 2018 Dec; 84():42-47. PubMed ID: 29183709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.